The
First Peptide for Expression Wrinkles
A
new advanced Anti-Aging Peptide
Argireline
is a unique new peptide that both reduces the degree of existing facial
wrinkles and has been demonstrated effective against their development.
It's been shown to inhibit the formation of the SNARE complex ( a core
of membrane proteins that mediates neuronal exocytosis) as well as catecholamine
release. These inhibitions confer anti-aging activity of Acetyl Hexapeptide-3(ARGIRELINE®);
they closely relate to the basic biochemical mechanisms of winkle formation.
Controlled studies have
also demonstrated that facial winkle depth can be reduced, especially in the
forehead and around he eyes, and that Acetyl Hexapeptide-3(ARGIRELINE®)
can prevent apparent facial skin ageing.
Cause of Facial Wrinkling
Facial wrinkling associated
with aging is caused and exacerbated by many factors. Beyond the physiological
pathways, molecular mechanisms involved in facial aging include changes in
collagen conformation, elastin polypeptide degradation, and problems of the
skin's lipid matrix. Recent studies clearly establish that these changes can
be significantly reduced by inhibiting SNARE complex formation.
The Technology
Acetyl Hexapeptide-3(ARGIRELINE®)'s specific sequence was shown to inhibit
the SNARE complex formation and catecholamine release. Once identified, it
was synthesized by solid phase peptide synthesis and then purified and characterized.
Efficacy Testing
In clinical testing, emulsion containing 10% of Acetyl Hexapeptide-3(ARGIRELINE®)
solution applied twice a day around eyes. It was observed that severity of
wrinkles around eyes decreased up to 17% after 15days of treatment and up
to 27% after 30days of treatment, sustaining the proposed biochemical mechanism
hypothesis.
In VIVO Testing
The skin replicas below show the improvement in facial smoothness at 30 days
post Acetyl Hexapeptide-3(ARGIRELINE®) treatment, compared with results
obtained without the incorporation of Acetyl Hexapeptide-3(ARGIRELINE®)
solution into the test cream.
Case 1:Treated
with an Acetyl Hexapeptide-3 containing cream after 30 days

0 days-Untreated Skin
30
days- Treated Skin
Case 2: Treated
with an Acetyl Hexapeptide-3 containing cream after 30 days
0 days-Untreated Skin 30
days- Treated Skin
Read
more about research studies on Argireline
|